Clean Air Act Enforcement in the Pharmaceutical Industry - Major Pharmaceutical Company to Pay $2.2 Million to EPA to Resolve Violations

more+
less-

On June 28, 2013, King Pharmaceuticals LLC (“King”) agreed to pay a $2.2 million fine and take measures to comply with the Clean Air Act (CAA) to resolve alleged failures to comply with major source requirements at its pharmaceutical manufacturing facility located in Bristol, Tennessee.

The settlement requires the facility to demonstrate compliance with CAA National Emission Standards for Pharmaceuticals Production (PharmaMACT regulations) and to apply for a Title V permit. The EPA’s PharmaMACT regulations impose “Maximum Achievable Control Technology” (MACT) standards, which are industry-specific measures that must be implemented to control hazardous air pollutants.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Clean Air Act, Clean Air Act Violations, Environmental Policies, EPA, Fines, Maximum Achievable Control Technology, National Emissions Standards, Pharmaceutical, Policy Violations

Published In: General Business Updates, Environmental Updates, Science, Computers & Technology Updates, Toxic Torts Updates, Zoning, Planning & Land Use Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »